The first human trial of a therapy designed to make older cells behave more like younger ones has begun. But did it reverse aging? No result has been reported yet.

In this video, Dr Deepa explains what was actually injected, why researchers started with only one eye, how ER-100 uses partial epigenetic reprogramming, and what this Phase 1 trial is really designed to discover.

We also examine a separate Klotho gene therapy being promoted through overseas clinics. What evidence supports it? Why don’t promising animal studies prove that people will live longer? And what risks should anyone understand before considering an experimental anti-aging treatment?

Covered in this video:
• ER-100 and partial epigenetic reprogramming.
• OSK and the Yamanaka factors.
• Why the treatment was injected into one eye.
• The doxycycline activation system.
• What researchers are monitoring for five years.
• Klotho and Minicircle gene therapy.
• Regulated trials versus treatments offered overseas.
• Tumour, immune and manufacturing risks.
• Questions to ask before considering experimental treatment.

The first participant was dosed in a Phase 1 study involving ER-100 for open-angle glaucoma and NAION. The primary purpose is to evaluate safety and tolerability—not to prove that human aging has been reversed.

#reverseaging #genetherapy #longevity.